When will the first RISUG procedure become commercially available?
RegolamentazioneOne-OffSalute e medicina4aManifold MarketsSenza KYCDati di risoluzione verificatiDiscretamente calibratoAvviso sulla qualità dei datiDati della fonte degradati
Dati al 26 ott 2026, 05:51 UTC · criterio pm-quality-4
Previsione della comunità attuale2035 or later 55.2%In testa tra 11 esiti
Previsori
2
Tipo di domanda
multiple choice
Metodologia
Play-money forecasting platform
Tipo di fonte
Previsione
Variazione 7g
0.0 pts
Dati di mercato
Aggiornato 8 ore fa
Obsoleto30 giu 25, 13:25 UTC30 dic 30, 14:21 UTC
Trend
Regole
Resolution Criteria
- This market will resolve to the first year in which the Reversible Inhibition of Sperm Under Guidance (RISUG) procedure becomes commercially available to the general public. "Commercially available" is defined as the procedure being offered by licensed medical practitioners outside of clinical trial settings, with necessary regulatory approvals in place.
- The resolution will be based on official announcements from regulatory bodies or reputable medical institutions confirming the availability of RISUG for public use.
- RISUG is a non-hormonal male contraceptive developed in India, involving an injection into the vas deferens to block sperm transport.
- Clinical trials have demonstrated its efficacy and safety, with a reported 97% success rate in preventing pregnancy.
- As of 2023, RISUG has completed Phase III clinical trials in India and is awaiting regulatory approval from the Drug Controller General of India (DCGI).
